Guardant Health, Inc. announced that its Shield multi-cancer detection (MCD) test was selected by the National Cancer Institute (NCI) for inclusion in its Vanguard study. This four-year pilot study will enroll up to 24,000 people to evaluate the feasibility of using MCD tests in future clinical trials for cancer screening.
The Shield MCD test was chosen based on the overall performance of its platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric cancers. Results from the NCI verification study are expected to be published in early 2025.
AmirAli Talasaz, Guardant Health co-CEO, expressed excitement about the potential for early detection of multiple cancers through a simple blood draw with the Shield MCD test. This selection is a critical step in demonstrating the value of Guardant's technology for broader cancer screening.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.